Navigation Links
Human Genome Sciences Begins Delivery of First-in-Class Anthrax Treatment to U.S. Strategic National Stockpile
Date:2/2/2009

ellular level. After protective antigen and the anthrax toxins are produced by the bacteria, protective antigen binds to the anthrax toxin receptor on cell surfaces and forms a protein-receptor complex that makes it possible for the anthrax toxins to enter the cells. ABthrax blocks the binding of protective antigen to cell surfaces and prevents the anthrax toxins from entering and killing the cells.

In contrast to the anthrax vaccine, the protection afforded by a single dose of ABthrax would be immediate following the rapid achievement of appropriate blood levels of ABthrax. In contrast to antibiotics, ABthrax acts against the deadly toxins produced by anthrax bacteria. It may also prevent and treat infections by antibiotic-resistant strains of anthrax. ABthrax was the first investigational agent against anthrax infection to be evaluated in a clinical study following the 2001 anthrax attacks in the United States. In 2003, ABthrax received a Fast Track Product designation from the FDA, as well as an Orphan Drug Designation for its use in the treatment of inhalation anthrax disease.

About the ABthrax Contract with the U.S. Government

In June 2006, the U.S. Government exercised its option to purchase ABthrax for the Strategic National Stockpile (Contract Number HHS010020050006C). HGS expects to receive $165 million in revenues from this award, with $150 million to come in the first half of 2009, following delivery of 20,000 doses of ABthrax, and the remainder to come upon FDA licensure of ABthrax. The purchase award was made by the HHS under the Project BioShield Act of 2004, which is designed to accelerate the development, purchase and availability of medical countermeasures for the Strategic National Stockpile. Under the contract, HGS has manufactured and is now delivering 20,000 treatment courses of ABthrax to the Stockpile. Also under the contract, the Company plans to file a Biologi
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Mardil Inc. Advances Its Novel Cardiac Device to First-In-Human Trials for Mitral Valve Regurgitation
2. Modigene Announces Positive Results of Pilot Toxicity Study of Its Long-Acting Human Growth Hormone hGH-CTP
3. Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference
4. Cequent to Present First Proof of Activity of an Oral RNAi Drug in Non-Human Primates at February Keystone Conference
5. 2008 Human Research Protection Award Recipients Announced
6. USD 12.5 m Funding for the Development of Intercells Vaccine Patch System for Pandemic Influenza From U.S. Department of Health and Human Services (HHS)
7. Vical Pandemic Influenza Vaccines Achieve T-Cell Responses and Cross-Clade Reactivity in Humans
8. SARS Vaccine Achieves Neutralizing Responses in First U.S. Human Trial
9. GeoVaxs Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America
10. Celladon Announces Presentation of Clinical Data From First-in-Human MYDICAR(R) Trial for Advanced Heart Failure at American Heart Association Scientific Sessions
11. Micromet Presents Data at the 23rd Annual Meeting of the International Society for Biological Therapy of Cancer on the Activity of Human Antibody Adecatumumab against KRAS-mutated Colon Cancer Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Inc. (NYSE: RMD ) today announced results for ... 30, 2014.  Revenue for the quarter was $415.2 million, flat ... percent decrease on a constant currency basis). Net income was ... quarter ended June 30, 2013. Diluted earnings per share for ... to the quarter ended June 30, 2013.  ...
(Date:7/31/2014)... Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC ... quarter ended June 30, 2014. Financial Results for ... Revenue Total revenue for the quarter ended June 30, 2014 ... ended June 30, 2013 primarily due to IMBRUVICA ® ... Total revenue for the six months ended June 30, 2014 ...
(Date:7/31/2014)... VIEW, Calif. , July 31, 2014 /PRNewswire/ ... today provided an update on its pipeline and ... 2014, Alexza expects to initiate a Phase 2a ... is being developed for the management of patients ... two new Staccato -based product candidates for ...
Breaking Medicine Technology:RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 2RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 3RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 4RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 5RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 6RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 7RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 8RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 9RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 10RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 11RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 12RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 13Pharmacyclics Reports Second Quarter 2014 Results 2Pharmacyclics Reports Second Quarter 2014 Results 3Pharmacyclics Reports Second Quarter 2014 Results 4Pharmacyclics Reports Second Quarter 2014 Results 5Pharmacyclics Reports Second Quarter 2014 Results 6Pharmacyclics Reports Second Quarter 2014 Results 7Pharmacyclics Reports Second Quarter 2014 Results 8Pharmacyclics Reports Second Quarter 2014 Results 9Pharmacyclics Reports Second Quarter 2014 Results 10Pharmacyclics Reports Second Quarter 2014 Results 11Pharmacyclics Reports Second Quarter 2014 Results 12Pharmacyclics Reports Second Quarter 2014 Results 13Pharmacyclics Reports Second Quarter 2014 Results 14Pharmacyclics Reports Second Quarter 2014 Results 15Pharmacyclics Reports Second Quarter 2014 Results 16Pharmacyclics Reports Second Quarter 2014 Results 17Pharmacyclics Reports Second Quarter 2014 Results 18Pharmacyclics Reports Second Quarter 2014 Results 19Pharmacyclics Reports Second Quarter 2014 Results 20Pharmacyclics Reports Second Quarter 2014 Results 21Pharmacyclics Reports Second Quarter 2014 Results 22Pharmacyclics Reports Second Quarter 2014 Results 23Pharmacyclics Reports Second Quarter 2014 Results 24
... Data presented by CSL Behring today suggest ... reduced risk of infection and missed school or work among ... at the 2011 American Academy of Allergy, Asthma and Immunology ... , one performed in the United States and one in ...
... 2011 HistoRx, Inc., announced today that the U.S. ... the company,s methods for standardization of digital microscopy instruments ... reproducible data that precisely relates to biomarker concentrations in ... digital pictures of an anatomic pathology specimen, a slide ...
Cached Medicine Technology:Study Demonstrates Relationship Between Subcutaneous IgG (SCIg) Dosage and Clinical Outcomes With Hizentra® Treatment in Patients With Primary Immunodeficiencies 2Study Demonstrates Relationship Between Subcutaneous IgG (SCIg) Dosage and Clinical Outcomes With Hizentra® Treatment in Patients With Primary Immunodeficiencies 3Study Demonstrates Relationship Between Subcutaneous IgG (SCIg) Dosage and Clinical Outcomes With Hizentra® Treatment in Patients With Primary Immunodeficiencies 4Study Demonstrates Relationship Between Subcutaneous IgG (SCIg) Dosage and Clinical Outcomes With Hizentra® Treatment in Patients With Primary Immunodeficiencies 5Study Demonstrates Relationship Between Subcutaneous IgG (SCIg) Dosage and Clinical Outcomes With Hizentra® Treatment in Patients With Primary Immunodeficiencies 6HistoRx Receives Fundamental Patent on Standardization of Results In Digital Pathology 2HistoRx Receives Fundamental Patent on Standardization of Results In Digital Pathology 3
(Date:7/31/2014)... 2014 You’re having a wonderful summer—sunning, gardening, ... suddenly developed chills and fever, headache, stiff neck, achey joints, ... flu-like illness, it could actually be the first sign of ... developing Lyme is greater than you might think. Until last ... in the U.S. annually. But the Centers for Disease Control ...
(Date:7/31/2014)... Two years in the making, Becoming Vegan: ... the research behind the latest scientific findings on the ... Melina, well-respected authorities on plant-based nutrition, put forth an ... adequate for people at all stages of life, including ... pregnant or lactating women. , Well-planned is the ...
(Date:7/31/2014)... Most mommy blogs are simple family journals, confessionals or ... all mothers from all walks of life. Magazines/websites ... high fashion or child rearing. When Felicia Blendermann became ... was so segmented. “I found myself visiting various sites ... search Google to get information on another. At the ...
(Date:7/31/2014)... 2014 (HealthDay News) -- Many black women put concerns ... research. It,s estimated by the U.S. Centers for ... black women in the United States are overweight or ... to avoid having to have their hair restyled or ... authors said. However, the researchers also noted a shift ...
(Date:7/31/2014)... study published today in Genes & Development ... Sciences Centre,s DNA Replication group, in collaboration with ... intricate mechanisms involved in the enzyme that governs ... sophisticated system using synthetic, chemical and structural biology ... involved in duplicating genetic information embraces DNA through ...
Breaking Medicine News(10 mins):Health News:Feel Like You Have A Summertime 'Flu'? It Could Be Lyme Disease 2Health News:Feel Like You Have A Summertime 'Flu'? It Could Be Lyme Disease 3Health News:New Book Presents Health Professionals With A Fully-Referenced, Meticulous Overview of the Research on Plant-Based Diets As A Healthy Choice 2Health News:New Book Presents Health Professionals With A Fully-Referenced, Meticulous Overview of the Research on Plant-Based Diets As A Healthy Choice 3Health News:Mommylish Launches Its Website 2Health News:Hairdo Trumps Exercise for Many Black Women, Study Finds 2Health News:Molecular gate that could keep cancer cells locked up 2
... close relatives proposed , , FRIDAY, Sept. 7 (HealthDay News) ... close relatives of people with coronary heart disease could ... Scottish researchers say. , "If you want primary prevention, ... groups with high risk," explained Dr. Jill Pell, professor ...
... Sept. 7 A group of golfers received,quick and ... surprising,natural remedy. Created by Earth,s Balance, Golfers Rx provided ... golfers with a week,or more of constant itching. ... the microscopic,oak leaf gall mite, also known as the ...
... G.,Rendell has proclaimed Sept. 9 - 15 as "Senior ... play in the lives of older,Pennsylvanians., "Senior community ... for older adults," said Governor Rendell. "The more than ... to stay active,and healthy, continue learning, share experiences and ...
... Inc. (NYSE: HB ) today announced its ... This dividend was declared by Hillenbrand,s,Board of Directors ... shareholders of,record as of September 14, 2007. ... organized into two operating companies,serving the health care ...
... or more alcoholic beverages a day may double their ... researchers at the University of Southern California (USC). The ... and is now available online. , This is the ... alcohol and endometrial cancer, says Veronica Wendy Setiawan, assistant ...
... Process, FRESNO, Calif., Sept. 7 Healthcare workers ... Joslin on,Thursday: the union-busting tactics going on at the ... there at risk. The workers instead urged Joslin ... who are interested in forming a union. Workers,could then ...
Cached Medicine News:Health News:Family History Has Strong Effect on Cardiac Risk 2Health News:Family History Has Strong Effect on Cardiac Risk 3Health News:Big Relief for Tiny Itch Mites Found in All Natural Spray Remedy 2Health News:Governor Rendell Proclaims Sept. 9-15 as 'Senior Community Center Week' 2Health News:Frequent alcohol consumption increases cancer risk in older women 2Health News:Hospital Workers: Management Threatens Patient Care 2
Liquid, ready-to-use, bar-coded Olympus reagents are convenient, economical easy-to-use and reliable. This is one of 122 tests standardized for use on the Olympus AU400e, AU640e, AU2700, and AU5400 C...
... the special needs of infants ... protects the littlest humans when ... vulnerable by providing the ideal ... of an infants body temperature ...
The design of the large pediatric underbody blanket conveniently warms the large child or small adult patient while allowing full access for surgeons and staff....
This pediatric blanket is a smaller version of the full body blanket, providing warmth to smaller patients during recovery....
Medicine Products: